Cargando…
Comparative evaluation of staging algorithms proven N2 non-small cell lung cancer treated by lung resection after neoadjuvant therapy
BACKGROUND: In this study, we aimed to compare the performances of clinical methods, minimally invasive methods, mediastinoscopy, and re-mediastinoscopy used in the restaging of patients receiving neoadjuvant therapy for pathologically proven N2. Our secondary objective was to determine the most opt...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bayçınar Medical Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9580280/ https://www.ncbi.nlm.nih.gov/pubmed/36303707 http://dx.doi.org/10.5606/tgkdc.dergisi.2022.21347 |
_version_ | 1784812358065979392 |
---|---|
author | İşgörücü, Özgür Çıtak, Necati Açıkmeşe, Barış Akalın Fener, Neslihan Büyükkale, Songül Sayar, Adnan |
author_facet | İşgörücü, Özgür Çıtak, Necati Açıkmeşe, Barış Akalın Fener, Neslihan Büyükkale, Songül Sayar, Adnan |
author_sort | İşgörücü, Özgür |
collection | PubMed |
description | BACKGROUND: In this study, we aimed to compare the performances of clinical methods, minimally invasive methods, mediastinoscopy, and re-mediastinoscopy used in the restaging of patients receiving neoadjuvant therapy for pathologically proven N2. Our secondary objective was to determine the most optimal algorithm for initial staging and restaging after neoadjuvant therapy. METHODS: Between April 2003 and August 2017, a total of 105 patients (99 males, 6 females; mean age: 54.5±8.2 years; range, 27 to 73 years) who were diagnosed with pathologically proven Stage 3A-B N2 non-small cell lung cancer and received neoadjuvant therapy and subsequently lung resection were retrospectively analyzed. Staging algorithm groups (Group 1=first mediastinoscopy-second clinic, Group 2=first mediastinoscopy-second minimally invasive, Group 3=first mediastinoscopy-second re-mediastinoscopy, and Group 4=first minimally invasive-second mediastinoscopy) were created and compared. RESULTS: In the first stage, N2 diagnosis was made in 90 patients by mediastinoscopy and in 15 patients by minimally invasive method. In the second stage, 44 patients were restaged by the clinical method, 23 by the minimally invasive method, 23 by re-mediastinoscopy, and 15 by mediastinoscopy. The false negativity rates of Groups 1, 2, 3, and 4 were 27.2%, 26.1%, 21.8%, and 13.3%, respectively. The most reliable staging algorithm was found to be the minimally invasive method in the first step and mediastinoscopy in the second step. The mean overall five-year survival rate was 46.3±4.4%, and downstaging in lymph node involvement was found to have a favorable effect on survival (54.3% vs. 21.8%, respectively; p=0.003). CONCLUSION: The staging method to be chosen before and after neoadjuvant therapy is critical in the treatment of Stage 3A-B N2 non-small cell lung cancer. In re-mediastinoscopy, the rate of false negativity increases due to technical difficulties and insufficient sampling. As the most optimal staging algorithm, the minimally invasive method is recommended in the first step and mediastinoscopy in the second step. |
format | Online Article Text |
id | pubmed-9580280 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Bayçınar Medical Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-95802802022-10-26 Comparative evaluation of staging algorithms proven N2 non-small cell lung cancer treated by lung resection after neoadjuvant therapy İşgörücü, Özgür Çıtak, Necati Açıkmeşe, Barış Akalın Fener, Neslihan Büyükkale, Songül Sayar, Adnan Turk Gogus Kalp Damar Cerrahisi Derg Original Article BACKGROUND: In this study, we aimed to compare the performances of clinical methods, minimally invasive methods, mediastinoscopy, and re-mediastinoscopy used in the restaging of patients receiving neoadjuvant therapy for pathologically proven N2. Our secondary objective was to determine the most optimal algorithm for initial staging and restaging after neoadjuvant therapy. METHODS: Between April 2003 and August 2017, a total of 105 patients (99 males, 6 females; mean age: 54.5±8.2 years; range, 27 to 73 years) who were diagnosed with pathologically proven Stage 3A-B N2 non-small cell lung cancer and received neoadjuvant therapy and subsequently lung resection were retrospectively analyzed. Staging algorithm groups (Group 1=first mediastinoscopy-second clinic, Group 2=first mediastinoscopy-second minimally invasive, Group 3=first mediastinoscopy-second re-mediastinoscopy, and Group 4=first minimally invasive-second mediastinoscopy) were created and compared. RESULTS: In the first stage, N2 diagnosis was made in 90 patients by mediastinoscopy and in 15 patients by minimally invasive method. In the second stage, 44 patients were restaged by the clinical method, 23 by the minimally invasive method, 23 by re-mediastinoscopy, and 15 by mediastinoscopy. The false negativity rates of Groups 1, 2, 3, and 4 were 27.2%, 26.1%, 21.8%, and 13.3%, respectively. The most reliable staging algorithm was found to be the minimally invasive method in the first step and mediastinoscopy in the second step. The mean overall five-year survival rate was 46.3±4.4%, and downstaging in lymph node involvement was found to have a favorable effect on survival (54.3% vs. 21.8%, respectively; p=0.003). CONCLUSION: The staging method to be chosen before and after neoadjuvant therapy is critical in the treatment of Stage 3A-B N2 non-small cell lung cancer. In re-mediastinoscopy, the rate of false negativity increases due to technical difficulties and insufficient sampling. As the most optimal staging algorithm, the minimally invasive method is recommended in the first step and mediastinoscopy in the second step. Bayçınar Medical Publishing 2022-07-29 /pmc/articles/PMC9580280/ /pubmed/36303707 http://dx.doi.org/10.5606/tgkdc.dergisi.2022.21347 Text en Copyright © 2022, Turkish Society of Cardiovascular Surgery https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Article İşgörücü, Özgür Çıtak, Necati Açıkmeşe, Barış Akalın Fener, Neslihan Büyükkale, Songül Sayar, Adnan Comparative evaluation of staging algorithms proven N2 non-small cell lung cancer treated by lung resection after neoadjuvant therapy |
title | Comparative evaluation of staging algorithms proven N2 non-small cell lung cancer treated by lung resection after neoadjuvant therapy |
title_full | Comparative evaluation of staging algorithms proven N2 non-small cell lung cancer treated by lung resection after neoadjuvant therapy |
title_fullStr | Comparative evaluation of staging algorithms proven N2 non-small cell lung cancer treated by lung resection after neoadjuvant therapy |
title_full_unstemmed | Comparative evaluation of staging algorithms proven N2 non-small cell lung cancer treated by lung resection after neoadjuvant therapy |
title_short | Comparative evaluation of staging algorithms proven N2 non-small cell lung cancer treated by lung resection after neoadjuvant therapy |
title_sort | comparative evaluation of staging algorithms proven n2 non-small cell lung cancer treated by lung resection after neoadjuvant therapy |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9580280/ https://www.ncbi.nlm.nih.gov/pubmed/36303707 http://dx.doi.org/10.5606/tgkdc.dergisi.2022.21347 |
work_keys_str_mv | AT isgorucuozgur comparativeevaluationofstagingalgorithmsprovenn2nonsmallcelllungcancertreatedbylungresectionafterneoadjuvanttherapy AT cıtaknecati comparativeevaluationofstagingalgorithmsprovenn2nonsmallcelllungcancertreatedbylungresectionafterneoadjuvanttherapy AT acıkmesebarıs comparativeevaluationofstagingalgorithmsprovenn2nonsmallcelllungcancertreatedbylungresectionafterneoadjuvanttherapy AT akalınfenerneslihan comparativeevaluationofstagingalgorithmsprovenn2nonsmallcelllungcancertreatedbylungresectionafterneoadjuvanttherapy AT buyukkalesongul comparativeevaluationofstagingalgorithmsprovenn2nonsmallcelllungcancertreatedbylungresectionafterneoadjuvanttherapy AT sayaradnan comparativeevaluationofstagingalgorithmsprovenn2nonsmallcelllungcancertreatedbylungresectionafterneoadjuvanttherapy |